Discussing China Biotech on the STAT Readout LOUD Podcast
May 3, 2018 --
As of April 30th, the Hong Kong Stock Exchange (HKEX) began accepting applications for IPO listings under its new biotech rule. For the first time ever, biotech companies that are at a developmental, pre-revenue stage will be able to list on the exchange. Charles Li, Chief Executive of HKEX, called this moment a Dawn of a New Era.
This is just one of a handful of important changes in the region that have the potential to catalyze a biotech boom in China. Others include government support of the sector, significant improvement and reform at the China Food and Drug Administration (CFDA), and a groundswell of high-quality science being conducted by researchers and entrepreneurs trained in drug development both home and abroad.
Brad Loncar, founder of the Loncar China BioPharma Index, joined Adam Feuerstein, Damian Garde, and Rebecca Robbins for their traditional Thursday recording of the STAT Readout LOUD Podcast to discuss these changes and what they might mean for the future of biotech in China. He recently returned from a trip to Shanghai and shares on the ground insights into what is happening there and why it matters to the industry.
Opinions expressed are those of the author or cancer researchers who are interviewed, are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
We hope you enjoy the program.
Episode #9: Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics.